10th Annual Update on Vascular Disease Session Two

10th Annual Update on Vascular Disease: Session Two

Release Date: August 15, 2019
Expiration Date: August 14, 2022

Estimated Time of Completion: This activity is expected to take approximately 1 hour per session to complete, for a total of 4 hours.

Program Agenda
Aortic Dissection: The Great Masquerader
Matthew Stull, MD

Thoraco-Abdominal Aneurysms: Current Outcomes
Jason Cho, MD

Aorto-Iliac Occlusive Disease: Endovascular and Open Options
Virginia Wong, MD

Panel Discussion/Audience Q&A
Drs. Gornik, Cho, Stull and Wong

 

Matthew Stull, MD
Assistant Residency Director,
Department of Emergency Medicine,
UH Cleveland Medical Center
Assistant Professor,
Case Western Reserve University School of Medicine
Dr. Stull reports no financial relationship with a commercial interest relevant to this activity.

Jae Cho, MD
Vascular Surgeon,
UH Harrington Heart & Vascular Institute
Clinical Professor,
Case Western Reserve University School of Medicine
Dr. Cho reports no financial relationship with a commercial interest relevant to this activity. Presentation will include discussion of unlabeled/investigational uses of a commercial product.

Virginia Wong, MD
Director, Vascular Services,
UH Richmond Medical Center, a campus of UH Regional Hospitals
Assistant Professor,
Case Western Reserve University School of Medicine
Dr. Wong reports no financial relationship with a commercial interest relevant to this activity. Presentation will include discussion of unlabeled/investigational uses of a commercial product.

Heather Gornik, MD
Co-Director, Vascular Center,
UH Harrington Heart & Vascular Institute
Associate Professor,
Case Western Reserve University School of Medicine
Dr. Gornik reports equity in Flexlife Health, and the CME Program has determined there is no conflict of interest.

Media
Recorded slides and audio presentation. Supplementary educational materials may include downloads of videos, print materials, slides or web pages.

Target Audience
This program is intended to update practicing internists, family medicine physicians, primary care physicians, cardiologists, hospitalists, vascular surgeons, podiatrists, physician assistants, nurse practitioners, nurses, residents and fellows on current topics in vascular disease.

Learning Objectives
After participating in this activity, participants will be able to:

Accreditation Statement

newlogo2

Case Western Reserve University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Case Western Reserve University School of Medicine designates this enduring material for a maximum of 4 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Session One: 1.0 Credits
Session Two: 1.0 Credits
Session Three: 1.0 Credits
Session Four: 1.0 Credits

Planning Committee
Vikram Kashyap, MD
Activity Director
Dr. Kashyap reports no financial relationship with a commercial interest relevant to this activity.

Jae Cho, MD
Dr. Cho reports no financial relationship with a commercial interest relevant to this activity. Presentation will include discussion of unlabeled/investigational uses of a commercial product.

Karem Harth, MD
Dr. Harth reports no financial relationship with a commercial interest relevant to this activity.

Mehdi Shishehbor, DO, MPH, PhD
Dr. Shishehbor has received advisory/consulting fees from Abbott, Boston Scientific, Medtronic, Philips, Spectranetics, Volcano, and Terumo, and the CME Program has determined there is no conflict of interest. Presentation will include discussion of unlabeled/investigational uses of a commercial product.

Disclosure Statement
The policy of Case Western Reserve University School of Medicine CME Program (CWRU CME) requires that the Activity Director, planning committee members and all activity faculty (that is, anyone in a position to control the content of the education activity) disclose to the activity participants all relevant financial relationships with commercial interests. Where disclosures have been made, conflicts of interest, real or apparent, must be resolved. Disclosure will be made to activity participants prior to the commencement of the activity. CWRU CME also requires that faculty make clinical recommendations based on the best available scientific evidence and that faculty identify any discussion of "off-label" or investigational use of pharmaceutical products or medical devices.

Instructions
To receive statements of credit for up to 4.0 AMA PRA Category 1 CreditsTM you must:

  1. Review the full content of all the recorded sessions
  2. Reflect on the content
  3. Complete the evaluation
  4. Claim your credit

Your credits will be recorded by the CWRU School of Medicine CME Program and made a part of your cumulative transcript.

Fee
There is no fee for this program.

To contact the CME Provider: E-mail Case Western Reserve University School of Medicine CME at medcme@case.edu

Resources

  1. Essentials of Clinical Evaluation, Chapter 1 in Rutherford Vascular Surgery. 6th Edition. Pages 1-13
  2. Patient Clinical Evaluation, Chapter 14 in Rutherford Vascular Surgery, 8th Edition, Pages 202-213
  3. Vasquez MA et al. Revision of the venous clinical severity score: Venous outcomes consensus statement: Special communication of the American Venous Forum Ad Hoc Outcomes Working Group. J Vasc Surg 2010;52:1387-1396
  4. Gerhard-Herman MD, et al. 2016 AHA/ACC Guideline of the Management of Patients with Lower Extremity Peripheral Artery Disease: Executive Summary. JACC 2017; Mar 21;69(11):1456-1508
  5. http://pertconsortium.org
  6. Kabrhel, C., Okechukwu, I., Hariharan, P. et al. Factors associated with clinical deterioration shortly after PE. Thorax. 2014; 69: 835–842
  7. Initial Experience with PERT Team Activation at MGH. CHEST 2016 150, 384-393DOI: (10.1016/j.chest.2016.03.011)
  8. Sista, A. K. et al. (2016). Research Priorities in Submassive Pulmonary Embolism: Proceedings from a Multidisciplinary Research Consensus Panel. Journal of Vascular and Interventional Radiology27(6), 787-794. DOI: 10.1016/j.jvir.2016.03.035
  9. Barnes G et al. Nuts and bolts of running a pulmonary embolism response team: results from an organizational survey of the National PERT™ Consortium members Hosp Prac2017 Aug;45(3):76-80. doi: 10.1080/21548331.2017.
  10. Taslakian B, Chawala D, Sista AK. A survey of submassive pulmonary embolism treatment preferences among medical and endovascular physicians. J Vasc Interv Radiol. 2017;28(12):1693–1699.e2
  11. Deadmon et al. Comparison of Emergency Department Patients to Inpatients Receiving a Pulmonary Embolism Response Team (PERT) Activation. Acad Emerg Med. 2017 Jul;24(7):814-821. doi: 10.1111/acem.13199. Epub 2017 May 11.
  12. Heit JA. Nat Rev Cardiol 2015;12:464-474
  13. Chest 2012;141(2) (Suppl)
  14. Cohen AT, et al N Engl J Med 2016;375:534-544
  15. Gibson CM, et al. Circulation 2017;135:848-655
  16. Yee MK, et al. J Thromb Thrombolysis 2018;45:1-8
  17. Kearon C, et al. Chest 2016;149:315-352